Felhasznált irodalom
*fontos közlemény
23
1
* HI Wu, JA Brown, MJ Dorie, és mtsai. Genome-Wide Identification of Genes Conferring Resistance to the
Anticancer Agents Cisplatin, Oxaliplatin, and Mitomycin C. Cancer Res 2004;64:3940-3948.
2
PA Clarke, R te Poele, P Workman. Gene expression microarray technologies in the development of new therapeutic
agents. Eur J Cancer 2004;40:2560-2591.
3
* S Gupta, RA Schoer, JE Egan, és mtsai. Inducible, reversible, and stable RNA interference in mammalian cells.
PNAS 2004;101:1927-1932.
4
RK Dawe. RNA interference on chromosomes. Nat Genet 2004;36:1141-42.
5
* DT McManus, A Olaru, SJ Meltzer. Biomarkers of Esophageal Adenocarcinoma and Barrett’s Esophagus. Cancer
Res 2004;64,1561–1569.
6 Fang M, Lew E, Klein M, és mtsai. DNA abnormailities as marker of risk for progression of Barrett’s esophagus to
Barrett adenocarcinoma: image cytometric DNA analysisin formalin-fixed tissues. Am J Gastroenterol 2004;99:1887-
1894
7 A WALCH, K SPECHT, H BRASELMANN, H STEIN, JR SIEWERT, U HOPT, H HOFLER, M WERNER.
COAMPLIFICATION AND COEXPRESSION OF GRB7 AND ERBB2 IS FOUND IN HIGH GRADE
INTRAEPITHELIAL NEOPLASIA AND IN INVASIVE BARRETT’S CARCINOMA. Int J Cancer 2004:112,747-
753.
8 K Dvorakova, CM Payne, L Ramsey, H Holubec, R Sampliner, J Dominguez, B Dvorak, H Bernstein, C Bernstein, A
Prasad, R Fass, H Cui, H Garewal. Increased Expression and Secretion of Interleukin-6 in Patients with Barrett’s
Esophagus. Clin Cancer Res 2004;10:2020-2028.
9 Chang Y, Gong J, Liu B, Zhang J, Dai F. Gene expression profiling in Barrett’s esophagus and cardia intestinal
metaplasia: A comparative analysis using cDNA microarray. World J Gastroenterol 2004; 10: 3194-3196.
10 E Tamoto, M Tada, K Murakawa, és mtsai. Gene-Expression Profile Changes Correlated with Tumor Progression and
Lymph Node Metastasis in Esophageal Cancer. Clin Cancer Res 2004;10: 3629-3638.
11 HP Yu, XL Wang, X Sun,és mtsai. Polymorphisms in the DNA repair gene XPD and susceptibility to esophageal
squamous cell carcinoma. Cancer Genet Cytogenet 2004;154:10-15.
12 H TAKEUCHI, S OZAWA, CH SHIH,és mtsai. LOSS OF p16INK4a EXPRESSION IS ASSOCIATED WITH
VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION IN SQUAMOUS CELL CARCINOMA OF THE
ESOPHAGUS. Int J Cancer 2004;109:483-490.
13 H KUMIMOTO, Y YAMANE, Y NISHIMOTO, és mtsai. FREQUENT SOMATIC MUTATIONS OF
MITOCHONDRIAL DNA IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA. Int J Cancer 2004;108:228-231.
14 J Davydova, LP Le, T Gavrikova, és mtsai. Infectivity-Enhanced Cyclooxygenase-2-Based Conditionally Replicative
Adenoviruses for Esophageal Adenocarcinoma Treatment. Cancer Res 2004;64: 4319-4324.
15 MA SHAMMAS, H KOLEY, DG BEER, és mtsai. Growth Arrest, Apoptosis, and Telomere Shortening of Barrett’sAssociated
Adenocarcinoma Cells by a Telomerase Inhibitor. Gastroenterology 2004;126: 1337-1346.
16 DMM QUEIROZ, JB GUERRA, GA ROCHA, és mtsai. IL1B and IL1RN Polymorphic Genes and Helicobacter
pylori cagA Strains Decrease the Risk of Reflux Esophagitis. Gastroenterology 2004;127:73-79.
17 Isomoto H, Saenko VA? Kanazawa Y, és mtsai. Enchanced expression of interleukin-8 and activation of NF-kBin
endoscopy negative gastroesophageal reflux disease. Am J Gastroenterol 2004;99:589-597.
18* Naohide Oue, Yoichi Hamai, Yoshitsugu Mitani, Shunji Matsumura, Yasuhiro Oshimo, Phyu Phyu Aung, Kazuya
Kuraoka, Hirofumi Nakayama, and Wataru Yasui. Gene Expression Profile of Gastric Carcinoma: Identification of
Genes and Tags Potentially Involved in Invasion, Metastasis, and Carcinogenesis by Serial Analysis of Gene
Expression. Cancer Res 64: 2397-2405.
19 H GEDDERT, S KIEL, E ISKENDER, AR FLORL, T KRIEG, S VOSSEN, HE GABBERT, M SARBIA,
CORRELATION OF hMLH1 AND HPP1 HYPERMETHYLATION IN GASTRIC,BUT NOT IN ESOPHAGEAL
AND CARDIAC ADENOCARCINOMA. Int J Cancer 2004:110, 208–211
20 G Clement, FT Bosman, C Fontolliet, és mtsai. Monoallelic Methylation of the APC Promoter Is Altered in Normal
Gastric Mucosa Associated with Neoplastic Lesions. Cancer Res 2004;64: 6867-6873.
21 Y Shimada, S Yamasaki, Y Hashimoto, T Ito, JKT Soma, Y Ino, Y Nakanishi, M Sakamoto, S Hirohashi, M Imamura.
Clinical Significance of Dysadherin Expression in Gastric Cancer Patients. Clin Cancer Res 2004; 10:2818-23.
22 E Miotto, S Sabbioni, A Veronese és mtsai. Frequent Aberrant Methylation of the CDH4 Gene Promoter in Human
Colorectal and Gastric Cancer. Cancer Res 2004;64: 8156-8159.
23 Y Sun, D Deng, WC You és mtsai. Methylation of p16 CpG Islands Associated with Malignant Transformation of
Gastric Dysplasia in a Population-Based Study. Clin Cancer Res 2004;10:5087-5093.
24 MS WU, LT CHEN, CT SHUN és mtsia. PROMOTER POLYMORPHISMS OF TUMOR NECROSIS FACTOR-a
ARE ASSOCIATED WITH RISK OF GASTRIC MUCOSA–ASSOCIATED LYMPHOID TISSUE LYMPHOMA. Int J
Cancer 2004;110:695-700.
25 T Kondo, N Oue, K Yoshida, és mtsai. Expression of POT1 is Associated with Tumor Stage and Telomere Length in
Gastric Carcinoma. Cancer Res 2004; 64: 523-529.
26 Ryungsa Kim, Manabu Emi, Kazuaki Tanabe, T Toge. Preclinical Evaluation of Antisense bcl-2 as a Chemosensitizer
for Patients with Gastric Carcinoma. Cancer 2004;101:2177-2186.
27 XH Jiang, SP Tu, JT Cui, és mtsai. Antisense Targeting Protein Kinase C a and b1 Inhibits Gastric Carcinogenesis.
Cancer Res 2004;64:5787-5794.
28 Yang JH, Zhang YC, Qian HQ.Survivin antisense oligodeoxynucleotide inhibits growth of gastric cancer cells. World
J Gastroenterol 2004;10:1121-1124.
29 K Ueda, M Iwahashi, I Matsuura, M Nakamori, M Nakamura, T Ojima, T Naka, K Ishida, K Matsumoto, T
Nakamura, H Yamaue. Adenoviral-mediated Gene transduction of the hepatocyte growth factor (HGF) antagonist, NK4,
suppresses peritoneal metastases of gastric cancer in nude mice. Eur J Cancer 2004;40:2135-2142.
30 Y Tsunemitsu, S Kagawa, N Tokunaga, és mtsai. Molecular therapy for peritoneal dissemination of xenotransplanted
human MKN-45 gastric cancer cells with adenovirus mediated Bax gene transfer. Gut 2004;53: 554-560.
31* HC Kang, IJ Kim, JH Park, és mtsai. Identification of Genes with Differential Expression in Acquired DrugResistant
Gastric Cancer Cells Using High-Density Oligonucleotide Microarrays. Clin Cancer Res 2004;10:272-284.
32 G HOLTMANN, W SIFFERT, S HAAG, és mtsai. G-Protein b3 Subunit 825 CC Genotype Is Associated With
Unexplained (Functional) Dyspepsia. Gastroenterology 2004; 126: 971-979.
33 MJ van Belzen, MM Vrolijk, JWR Meijer és mtsai. A genomwide screen in a four-generation Dutch familywith
celiac disease: evidence for linkage to chromosomes 6 and 9. Am J Gastroenterol 2004;99:466-471.
34 S Gonzalez, L Rodrigo ,A Lopez-Vasquez, és mtsai. Association of MCH class I related gene B (MICB) to celiac
disease. Am J Gastroenterol 2004;99:676-680.
35 B Diosdado, M C Wapenaar, L Franke, és mtsai. A microarray screen for novel candidate genes in coeliac disease
pathogenesis. Gut 2004;53:944–951.
36 Van Belzen MJ, Mulder CJJ, Zherankova A és mtsai. CTLA4+49 AG and CT60 polymorphisms in Dutch coeliac
disease patients. Eur J Hum Genet 2004;12:782-785.
37* S KANAOKA, KI YOSHIDA, N MIURA, és mtsai. Potential Usefulness of Detecting Cyclooxygenase 2
Messenger RNA in Feces for Colorectal Cancer Screening. Gastroenterology 2004;127:422-427.
38 K SONG, AM FENDRICK, U LADABAUM. Fecal DNA Testing Compared With Conventional Colorectal Cancer
Screening Methods: A Decision Analysis. Gastroenterology 2004;126: 1270-1279.
39* TF Imperiale, DF Ransohoff, SH Itzkowitz, és mtsai. Fecal DNA versus Fecal Occult Blood for Colorectal-Cancer
Screening in an Average-Risk Population. NEJM 2004;351:2704-2714.
40 SCC Wong, SFE Lo, MT Cheung, KOE Ng, CW Tse, BSP Lai, KC Lee,1 YMD Lo. Quantification of Plasma bCatenin
mRNA in Colorectal Cancer and Adenoma Patients. Clin Cancer Res 2004;10: 1613-1617.
41 E ROSIVATZ, I BECKER, M BAMBA, C SCHOTT, J DIEBOLD, D MAYR, H HOFLER, KF BECKER.
NEOEXPRESSION OF N-CADHERIN IN E-CADHERIN POSITIVE COLON CANCERS. Int J Cancer 2004;111:
711-719.
42 A NOBUOKA, T TAKAYAMA, K MIYANISHI, és mtsai. Glutathione-S-Transferase P1-1 Protects Aberrant Crypt
Foci From Apoptosis Induced by Deoxycholic Acid. Gastroenterology 2004;127:428-443.
43* PR Nambiar, M Nakanishi, R Gupta, E Cheung, A Firouzi, XJ Ma, C Flynn, M Dong, K Guda, J Levine, R Raja, L
Achenie, DW Rosenberg. Genetic signatures of High- and Low-Risk Aberrant Crypt Foci in a Mouse Model of
Sporadic Colon Cancer. Cancer Res 2004;64: 6394-6401.
44 Lakatos PL, Halász J, Keresztes K, Fuszek P, Jäckel M, Poros A, Morvay K, Lakatos L. A familiaris adenomatosus
polyposis (FAP)-ról egy eset kapcsán. Orvosi Hetilap 2004;145:813-817.
45 T VENESIO, S MOLATORE, F CATTANEO, és mtsai. High Frequency of MYH Gene Mutations in a Subset of
Patients With Familial Adenomatous Polyposis. Gastroenterology 2004;126:1681-1685.
46 C FLEISCHMANN, J PETO, J CHEADLE, B SHAH, J SAMPSON, RS HOULSTON. COMPREHENSIVE
ANALYSIS OF THE CONTRIBUTION OF GERMLINE MYH VARIATION TO EARLY-ONSET COLORECTAL
CANCER. Int J Cancer 2004;109:554-558.
47* V GISMONDI, M META, L BONELLI, P RADICE, P SALA, L BERTARIO, A VIEL, M FORNASARIG, A
ARRIGONI, M GENTILE, M PONZ DE LEON, L ANSELMI, C MARENI, P BRUZZI, L VARESCO. PREVALENCE
OF THE Y165C, G382D AND 1395delGGA GERMLINE MUTATIONS OF THE MYH GENE IN ITALIAN
PATIENTS WITH ADENOMATOUS POLYPOSIS COLI AND COLORECTAL ADENOMAS. Int J Cancer 2004;109:
680-684.
48* L WANG, LM BAUDHUIN, LA BOARDMAN, és mtsai. MYH Mutations in Patients With Attenuated and Classic
Polyposis and With Young-Onset Colorectal Cancer Without Polyps. Gastroenterology 2004;127:9-16.
49 MD Crabtree, C Fletcher, M Churchman, és mtsai. Analysis of candidate modifier loci for the severity of colonic
familial adenomatous polyposis, with evidence for the importance of the N-acetyl transferases. Gut 2004;53:271-276.
50 L Bertario, A Russo, P Sala, és mtsai. APC Genotype Is Not a Prognostic Factor in Familial Adenomatous Polyposis
Patients With Colorectal Cancer. Dis Colon Rectum 2004;47:1662-1669.
51 YMC HENDRIKS, A WAGNER, H MORREAU, és mtsai. Cancer Risk in Hereditary Nonpolyposis Colorectal
Cancer Due to MSH6 Mutations: Impact on Counseling and Surveillance. Gastroenterology 2004; 127: 17-26.
52* AE DE JONG, H MORREAU, M VAN PUIJENBROEK, és mtsai. The Role of Mismatch Repair Gene Defects in
the Development of Adenomas in Patients With HNPCC. Gastroenterology 2004;125:42-48.
53 JS Jones, X Chi, X Gu, és mtsai. p53 Polymorphism and Age of Onset of Hereditary Nonpolyposis Colorectal Cancer
in a Caucasian Population. Clin Cancer Res 2004;10: 5845-5849.
54AE de Jong, M van Puijenbroek, Y Hendriks, és mtsai. Microsatellite Instability, Immunohistochemistry, and
Additional PMS2 Staining in Suspected Hereditary Nonpolyposis Colorectal Cancer. Clin Cancer Res 2004;10:972-980.
55 TL Chan, YW Chan, JWC Ho, és mtsai. MSH2 c.1452–1455delAATG Is a Founder Mutation and an Important Cause
of Hereditary Nonpolyposis Colorectal Cancer in the Southern Chinese Population. Am J Hum Genet 2004; 74:1035-
1042.
56 K CEDERQUIST, M EMANUELSSON, I GORANSSON, E HOLINSKI-FEDER, Y MULLER-KOCH, I
GOLOVLEVA, H GRONBERG. MUTATION ANALYSIS OF THE MLH1, MSH2 AND MSH6 GENES IN PATIENTS
WITH DOUBLE PRIMARY CANCERS OF THE COLORECTUM AND THE ENDOMETRIUM: A POPULATIONBASED
STUDY IN NORTHERN SWEDEN. Int J Cancer 2004; 109: 370-376.
57 SM Lipkin, LS Rozek, G Rennert, és mtsai. The MLH1 D132H variant is associated with susceptibility to sporadic
colorectal cancer. Nat Genet 2004;36:694-699.
58* M Keller, R Jost, M Kadmon, és mtsai. Acceptance of and Attitude Toward Genetic Testing for Hereditary
Nonpolyposis Colorectal Cancer: A Comparison of Participants and Nonparticipants in Genetic Counseling. Dis Colon
Rectum 2004;47:153-162.
59 W LIM, S OLSCHWANG, JJ KELLER, és mtsai. Relative Frequency and Morphology of Cancers in STK11
Mutation Carriers. Gastroenterology 2004;126:1788-1794.
60 L UDD, P KATAJISTO, DJ ROSSI, és mtsai. Suppression of Peutz–Jeghers Polyposis by Inhibition of
Cyclooxygenase-2. Gastroenterology 2004;127:1030-1037.
61 Le Meur N, Martin C, Saugier-Veber P, és mtsai. Complete germline deletion of the STK11 gene in a family with
PeutzJeghers syndrome. Eur J Hum Genet 2004;12:415-418.
62 Fogt F, Brown CA, Badizadegan K, és mtsai. Low prevalence of loss of heterozygosity and SMAD4 mutations in
sporadic and familial juvenile polyposis syndrome-associated juvenile polyps. Am J Gastroenterol 2004;99:2025-31.
63 L Sarli, L Bottarelli, C Azzoni, N Campanini, G Di Cola, G Bader, D Iusco, C Salvemini, G Caruso, E Donadei, S
Pizzi, T D’Adda, C Renato, L Roncoroni, C Bordi. Abnormal Fhit protein expression and high frequency of
microsatellite instability in sporadic colorectal cancer. Eur J Cancer 2004;40: 1581-1588.
64 J Plaschke, S Kruger, B Jeske, F Theissig, FR Kreuz, S Pistorius, HD Saeger, I Iaccarino, G Marra, HK Schackert.
Loss of MSH3 Protein Expression Is Frequent in MLH1-Deficient Colorectal Cancer and Is Associated with Disease
Progression1. Cancer Res 2004;64:864-870.
65 G Deng, IBell, S Crawley, J Gum, JP Terdiman, BA Allen, B Truta, MH Sleisenger, YS Kim. BRAF Mutation Is
frequently Present in Sporadic Colorectal Cancer with Methylated hMLH1, But Not in Hereditary Nonpolyposis
Colorectal Cancer. Clin Cancer Res 2004;10:191-195.
66* T Kambara, LA Simms, VLJ Whitehall, és mtsai. BRAF mutation is associated with DNA methylation in serrated
polyps and cancers of the colorectum. Gut 2004;53:1137–1144.
67 MM de Jonga, RMW Hofstrab, KA Kooi, és mtsai. No association between two MLH3 variants (S845G and
P844L)and colorectal cancer risk. Cancer Genet Cytogenet 2004;152:70-71.
68 Y Mori, J Yin, F Sato, A Sterian, LA Simms, FM Selaru, K Schulmann, Y Xu, A Olaru, S Wang, E Deacu, JM
Abraham, J Young, BA Leggett, SJ Meltzer. Identification of Genes Uniquely Involved in Frequent Microsatellite
Instability Colon Carcinogenesis by Expression Profiling Combined with Epigenetic Scanning. Cancer Res 2004;64:
2434-2438.
69 A Goel, CN Arnold, D Niedzwiecki, JM Carethers, JM Dowell, L Wasserman, C Compton, RJ Mayer, MM
Bertagnolli, CR Boland. Frequent Inactivation of PTEN by Promoter Hypermethylation in Microsatellite InstabilityHigh
Sporadic Colorectal Cancers. Cancer Res 2004;64: 3014-3021.
70 Y Parc, S Gueroult, N Mourra, és mtsai. Prognostic significance of microsatellite instability determined by
immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer. Gut 2004;53:371–375.
71 SB Lim, SY Jeong, MR Lee. Prognostic significance of microsatellite instability in sporadic colorectal cancer. Int J
Colorectal Dis 2004;19:533-537.
72 U Schiemann, Y Müller-Koch, M Gross, és mtsai. Extended Microsatellite Analysis in Microsatellite Stable, MSH2
and MLH1 Mutation-Negative HNPCC Patients: Genetic Reclassification and Correlation with Clinical Features.
Digestion 2004;69:166-176.
73 AHC BAI, JHM TONG, KF TO, MWY CHAN, EPS MAN, KW LO, JFY LEE, JJY SUNG, WK LEUNG.
PROMOTER HYPERMETHYLATION OF TUMOR-RELATED GENES IN THE PROGRESSION OF
COLORECTAL NEOPLASIA. Int J Cancer 2004;112: 846-853.
74 NACS Wong, MP Britton, GS Choi, és mtsai. Loss of CDX1 expression in colorectal carcinoma: Promoter
methylation, mutation, and loss of heterozygosity analyses of 37 cell lines. PNAS 2004; 101-574-579.
75 AH Ting, KW Jair, H Suzuki, és mtsai. CpG island hypermethilation is maintained in human colorectal cells after
RNA-i mediated depletion of DNMT1. Nat Genet 2004;37:1-3.
76 OE Bechter, Y Zou, W Walker, WE Wright, JW Shay. Telomeric Recombination in Mismatch Repair Deficient
Human Colon Cancer Cells after Telomerase Inhibition. Cancer Res 2004;64: 3444-3451.
77 Aust DE, Muders M, Kohler A, és mtsai. Prognostic relevance of 20q13 gains in sporadic colorectal cancers: a FISH
analysis. Scand J Gastroenterol 2004;39:766–772.
78 G Kurzawski, J Suchy, J Kładny, Ewa Grabowska, M Mierzejewski, A Jakubowska, T Debniak, C Cybulski, E
Kowalska, Z Szych, W Domagała, RJ Scott, J Lubinski. The NOD2 3020insC Mutation and the Risk of Colorectal
Cancer. Cancer Res 2004;64: 1604-1606.
79 P Alhopuro, T Ahvenainen, JP Mecklin, és mtsai. NOD2 3020insC Alone Is Not Sufficient for Colorectal Cancer
Predisposition. Cancer Res 2004;64:7245-7247.
80 Fuszek P, Lakatos P, Tabak A, és mtsai. Relationship between serum calcium and CA 19-9 levels in colorectal cancer.
World J Gastroenterol 2004; 10: 1890-1892.
81 JM FERRAZ, F ZINZINDOHOUE, T LECOMTE, és mtsai. IMPACT OF GSTT1, GSTM1, GSTP1 AND NAT2
GENOTYPES ON KRAS2 AND TP53 GENE MUTATIONS IN COLORECTAL CANCER. Int J Cancer 2004;110:183-
187.
82 V ADLEFF, E HITRE, I KOVES, Z OROSZ, A HAJNAL, J KRALOVANSZKY. HETEROZYGOTE DEFICIENCY
IN THYMIDYLATE SYNTHASE ENHANCER REGION POLYMORPHISM GENOTYPE DISTRIBUTION IN
HUNGARIAN COLORECTAL CANCER PATIENTS. Int J Cancer 2004;108:852-856.
83 F De Vita, M Orditura, E Lieto, S Infusino, F Morgillo, E Martinelli, P Castellano, C Romano, F Ciardiello, G
Catalano, C Pignatelli, G Galizia. Elevated Perioperative Serum Vascular Endothelial Growth Factor Levels in Patients
with Colon Carcinoma. Cancer 2004;100: 270-278.
84 P Marzola, A Degrassi, L Calderan, P Farace, C Crescimanno, E Nicolato, A Giusti, E Pesenti, A Terron, A Sbarbati, T
Abrams, L Murray, F Osculati1. In Vivo Assessment of Antiangiogenic Activity of SU6668 in an Experimental Colon
Carcinoma Model. Clin Cancer Res 2004;10: 739-750.
85 Guo J, Verma UN, Gaynor RB, és mtsai. Enhanced chemosensitivity to irinotecan by RNA interference-mediated
down-regulation of the nuclear factor-kappaB p65 subunit. Clin Cancer Res 2004;10:3333-41.
86 A Mohr, G Henderson, L Dudus, és mtsai. AAV-encoded expression of TRAIL in experimental human colorectal
cancer leads to tumor regression. Gene Therapy 2004;11:534-543.
87 Jiang YA, Luo HS, Fan LF, Jiang CQ, Chen WJ.Effect of antisense oligodeoxynucleotide of telomerase RNA on
telomerase activity and cell apoptosis in human colon cancer. World J Gastroenterol 2004;10:443-445.
88 P Ryan, RG Kelly, G Lee, és mtsai. Bacterial DNA within granulomas of patients with Crohn’s disease – detedtion by
Laser capture microdissection and PCR. Am J Gastroenterol 2004;99:1539-1543.
89* T AHMAD, CP TAMBOLI, D JEWELL, JF COLOMBEL. Clinical Relevance of Advances in Genetics and
Pharmacogenetics of IBD. Gastroenterology 2004;126: 1533-1549.
90* VD Peltekova, RF Wintle, LA Rubin és mtsai. Functional variants of OCTN cation transporter genes are associated
with Crohn disease. Nat Genet 2004;36:471-475.
91 Low JH, Williams FA, Yang X, és mtsai. Inflammatory Bowel Disease Is Linked to 19p13 and Associated with
ICAM-1. Inflammatory Bowel Diseases 2004;10:173-181.
92 Stoll M, Corneliussen B, Costello CM, és mtsai. Genetic variation in DLG5 is associated with inflammatory bowel
disease. Nat Genet 2004;36:476-480.
93 Barmada MM, Brant SR, Nicolae DL, és mtsai. A Genome Scan in 260 Inflammatory Bowel Disease-Affected
Relative Pairs. Inflammatory Bowel Diseases 2004;10:15-22.
94* Lakatos L, Lakatos PL, Willheim-Polli C, Reinisch W, Ferenci P, Tulassay Z, Molnar T, Kovacs A, Papp J,
Hungarian IBD Study Group, Szalay F. NOD2/CARD15 mutációk magyarországi Crohn betegekben. Genotípusfenotípus
vizsgálat. Orvosi Hetilap 2004;145:1403-11.
95* Newmann B, Silverberg MS, Gu X, és mtsai. CARD15 and HLA DRB1 alleles influence susceptibility and
localization in Crohn’s disease. Am J Gastroenterol 2004;99:307-315.
96 Esters N, Pierik M, van Steen K és mtsai. Transmission of CARD15 (NOD2) variants within families of patients with
inflammatory bowel disease. Am J Gastroenterol 2004;99:299-305.
97 Heresbach D, Gicquel-Douabin V, Birebent B és mtsai. NOD2/CARD15 gene polymorphisms in Crohn’s disease: a
genotype-phenotype analysis. Eur J Gastroenterol Hepatol 2004;16:55-62.
98 Nunez C, Barreiro M, Dominguez-Munoz JE, és mtsai. CARD15 mutation in pateints with Crohn’s diseasein a
homogenous Spanish population. Am J Gastroenterol 2004;99:450-456.
99 Vavassori P, Borgiani P, Biancone L, és mtsai. CARD15 Mutation Analysis in an Italian Population: Leu1007fsinsC
but Neither Arg702Trp nor Gly908Arg Mutations Are Associated with Crohn’s Disease. Inflammatory Bowel Diseases
2004;10:116-121.
100 Karban A, Watermann M, Panhuysen CI, és mtsai. NOD2/CARD15 genotype and phenotype differences between
Ashkenazi and Sephardic Jews with Crohn’s disease. Am J Gastroenterol 2004;99:1134-40.
101 T Tukel, A Shalata, D Present, és mtsai. Crohn Disease: Frequency and Nature of CARD15 Mutations in Ashkenazi
and Sephardi/Oriental Jewish Families. Am J Hum Genet 2004;74: 623-636.
102 J Wehkamp, J Harder, M Weichenthal, és mtsai. NOD2 (CARD15) mutations in Crohn’s disease are associated with
diminished mucosal a-defensin expression. Gut 2004;53:1658-1664.
103 D Franchimont, S Vermeire, H El Housni, és mtsai. Deficient host-bacteria interactions in inflammatory bowel
disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn’s disease and ulcerative
colitis. Gut 2004;53:987-992.
104 D RACHMILEWITZ, K KATAKURA, F KARMELI, és mtsai. Toll-Like Receptor 9 Signaling Mediates the Antiinflammatory
Effects of Probiotics in Murine Experimental Colitis. Gastroenterology 2004;126:520-528.
105 S Vermeire, P Rutgeerts, K Van Steen, és mtsai. Genome wide scan in a Flemish inflammatory bowel disease
population: support for the IBD4 locus, population heterogeneity, and epistasis. Gut 2004;53:980-986.
106 HJ Kim, M Camilleri, PJ Carlson, és mtsai. Association of distinct a2 adrenoceptor and serotonin transporter
polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut 2004;53:829-837.
107 DF CALVISI, VM FACTOR, S LADU, és mtsai. Disruption of b-Catenin Pathway or Genomic Instability Define
Two Distinct Categories of Liver Cancer in Transgenic Mice. Gastroenterology 2004;126:1374-1386.
108 N Harada, H Oshima, M Katoh. Hepatocarcinogenesis in Mice with b-Catenin and Ha-Ras Gene Mutations. Cancer
Res 2004;64: 48-54.
109 MY Cha, CM Kim, YM Park, és mtsa. Hepatitis B Virus X Protein Is Essential for the Activation of Wnt/b-Catenin
Signaling in Hepatoma Cells. Hepatology 2004;39:1683-93.
110 T Chiba, O Yokosuka, M Arai, és mtsai. Identification of genes up-regulated by histone deacetylase inhibition with
cDNA microarray and exploration of epigenetic alterations on hepatoma cells. J Hepatol 2004;41:436-445.
111 A Lechel, MP Manns, KL Rudolph. Telomeres and telomerase: new targets for the treatment of liver cirrhosis and
hepatocellular carcinoma. J Hepatol 2004;41:491-497.
112* A Satyanarayana, MP Manns, KL Rudolph. Telomeres and Telomerase:a Dual Role in Hepatocarcinogenesis.
Hepatology 2004;40:276-283.
113 RR Plentz, M Caselitz, JS Bleck, és mtsai. Hepatocellular Telomere Shortening Correlates With Chromosomal
Instability and the Development of Human Hepatoma. Hepatology 2004;40:80-86.
114 Shao JY, Gao HY, Li YH, és mtsai. Quantitative detection of common deletion of mitochondrial DNA in
hepatocellular carcinoma and hepatocellular nodular hyperplasia. World J Gastroenterol 2004; 10: 1560-1564.
115* Yutaka Midorikawa,1,3 Shuichi Tsutsumi,1 Kunihiro Nishimura, és mtsai. Distinct Chromosomal Bias of Gene
Expression Signatures in the Progression of Hepatocellular Carcinoma. Cancer Res 2004;64:7263-7270.
116* YS Jou, CS Lee, YH Chang és mtsai. Clustering of Minimal Deleted Regions Reveals Distinct Genetic Pathways of
Human Hepatocellular Carcinoma. Cancer Res 2004;64: 3030-3036.
117* SY Neo, CK Leow, VB Vega, és mtsai. Identification of Discriminators of Hepatoma by Gene Expression Profiling
Using a Minimal Dataset Approach. Hepatology 2004;39:944-953.
118 S Itoh, T Maeda, M Shimada és mtsai. Role of Expression of Focal Adhesion Kinase in Progression of
Hepatocellular Carcinoma. Clin Cancer Res 2004;10:2812-2817.
119 RT Poon, KK Chung,, ST Cheung, és mtsai. Clinical Significance of Thrombospondin 1 Expression in
Hepatocellular Carcinoma. Clin Cancer Res 2004;10: 4150-4157.
120 S Kremer-Tal, HL Reeves, G Narla, és mtsai. Frequent Inactivation of the Tumor Suppressor Kruppel-like Factor 6
(KLF6) in Hepatocellular Carcinoma. Hepatology 2004;40:1047-1052.
121* Y Kurokawa, R Matoba, I Takemasa, és mtsai. Molecular-based prediction of early recurrence in hepatocellular
carcinoma. J Hepatol 2004;41:284-291.
122 JM Llovet, E Wurmbach. Gene expression profiles in hepatocellular carcinoma: not yet there. J Hepatol
2004;41:336-339.
123 Y Wang, N Kato, Y Hoshida, és mtsai. UDP-Glucuronosyltransferase 1A7 Genetic Polymorphisms Are Associated
with Hepatocellular Carcinoma in Japanese Patients with Hepatitis C Virus Infection. Clin Cancer Res 2004;10: 2441-
2446.
124 Pellicano R, Mazzaferro V, Grigioni WF, Cutufia MA, Fagoonee S, Silengo L, Rizzetto M, Ponzetto A. Helicobacter
species sequences in liver samples from patients with and without hepatocellular carcinoma. World J Gastroenterol
2004; 10: 598-601.
125 R Sato, C Maesawa, K Fujisawa, és mtsai. Prevention of critical telomere shortening by oestradiol in human normal
hepatic cultured cells and carbon tetrachloride induced rat liver fibrosis. Gut 2004;53:1001-1009.
126 YI Yamashita, M Shimada, R Minagawa, és mtsai. Muscle-targeted interleukin-12 gene therapy of orthotopic
hepatocellular carcinoma in mice using in vivo electrosonoporation. Mol Cancer Ther 2004;2004;3:1177-1182.
127 V Schmitz, L Wang, M Barajas, és mtsai. Treatment of colorectal and hepatocellular carcinomas by adenoviral
mediated gene transfer of endostatin and angiostatin-like molecule in mice. Gut 2004;53:561-567.
128 Li PY, Lin JS, Feng ZH, és mtsai. Combined gene therapy of endostatin and interleukin 12 with
polyvinylpyrrolidone induces a potent antitumor effect on hepatoma. World J Gastroenterol 2004; 10: 2195-2200.
129 A Salvi, B Arici, G De Petro, S Barlati. Small interfering RNA urokinase silencing inhibits invasion and migration of
human hepatocellular carcinoma cells. Mol Cancer Ther 2004;3:671-678.
130 Liu SX, Sun WS, Cao Ylés mtsai. Antisense oligonucleotide targeting at the initiator of hTERT arrests growth of
hepatoma cells. World J Gastroenterol 2004; 10:366-370.
131 Irving J, Wang Z, Powell S, és mtsai. Conditionally replicative adenovirus driven by the human telomerase promoter
provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Therapy 2004;11:174-185.
132 Z Pei, L Chu, W Zou, és mtsai. An Oncolytic Adenoviral Vector of Smac Increases Antitumor Activity of TRAIL
Against HCC in Human Cells and in Mice. Hepatology 2004;39:1371-1381.
133 M Hopfner, AP Sutter, A Huether, és mtsai. Targeting the epidermal growth factor receptor by gefitinib (‘Iressa’) for
treatment of hepatocellular carcinoma. J Hepatol 2004;41 xx.
134 L Ge, Z Wang, M Wang, és mtsai. Involvement of c-Myc in growth inhibition of Hep 3B human hepatoma cells by a
vitamin K analog. J Hepatol 2004;41:823-829.
135* A Pietrangelo. Hereditary hemochromatosis- A new look a tan old disease. NEJM 2004;350:2383-2397.
136* A Pietrangelo. Non-HFE hemochromatosis. Hepatology 2004;39:21-29.
137* KJH Robson, AT Merryweather-Clarke, E Cadet, és mtsai. Recent advances in understanding haemochromatosis: a
transition state. J Med Genet 2004;41:721-730.
138 M DE GOBBI, S D’ANTICO, F CASTAGNO, és mtsia. Screening selected blood donors with biochemical iron
overload for hemochromatosis: a regional experience. Haematologica2004;89:1161-1167.
139* G Papanikolau, ME Samuels, EH Ludwig, és mtsai. Mutations in HFE2 cause iron overload in chromosome 1plinked
juvenile hemochromatosis . Nat Genet 2004;36:77-82.
140 M BENSAID, S FRUCHON, C MAZERES, és mtsai. Multigenic Control of Hepatic Iron Loading in a Murine
Model of Hemochromatosis. Gastroenterology 2004;126:1400-1408.
141 E Nemeth, A Roetto, G Garozzo, és mtsai. HEPCIDIN IS DECREASED IN TFR2-HEMOCHROMATOSIS. Blood
2004, prepublished online October 14, 2004; DOI 10.1182/blood-2004-08-3042
142 Nagy Z, Koszo F, Par A, Emri G, Horkay I, Horanyi M, Karadi O, Rumi Jr., G, Morvay M, Varga V, Dobozy A,
Mozsik G. Hemochromatosis (HFE) gene mutations and hepatitis C virus infection as risk factors for porphyria cutanea
tarda in Hungarian patients. Liver Int 2004: 24: 16–20.
143 Geier A, Reugels M, Weiskirchen R, és mtsai. Common heterozygous hemochromatosis gene mutations are risk
factors for inflammation and fibrosis in chronic hepatitis C. Liver Int 2004: 24: 285–294.
144* F Penin, J Dubuisson, FA Rey, és mtsai. Structural Biology of Hepatitis C Virus. Hepatology 2004;39:5-19.
145 Abbott WGH, Rigopoulou E, Haigh P, Cooksley H, Mullerova I, Novelli M, Winstanley A, Williams R, Naoumov
NV. Single nucleotide polymorphisms in the interferon-g and interleukin-10 genes do not influence chronic hepatitis C
severity or t-cell reactivity to hepatitis C virus. Liver Int 2004: 24: 90–97.
146 M Romero-Gomez, M A Montes-Cano, M A Otero-Fernandez, és mtsai. SLC11A1 promoter gene polymorphisms
and fibrosis progression in chronic hepatitis C. Gut 2004;53:446-450.
147 K Machida, KTN Cheng, VMH. Sung, és mtsai. Hepatitis C virus induces a mutator phenotype: Enhanced mutations
of immunoglobulin and protooncogenes. PNAS 2004;101:4262-4267.
148 SM McKiernan, R Hagan, M Curry, és mtsai. Distinct MHC Class I and II Alleles Are Associated With Hepatitis C
Viral Clearance, Originating From a Single Source. Hepatology 2004;40:108-114.
149 M Pascu, P Martus, M Hohne, és mtsai. Sustained virological response in hepatitis C virus type 1b infected patients
is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences.
Gut 2004;53:1345-51.
150 T Mueller, A Mas-Marques, C Sarrazin, és mtsai. Influence of interleukin 12B (IL12B) polymorphisms on
spontaneous and treatment-induced recovery from hepatitis C virus infection. J Hepatol 2004;41:652-658.
151* G Randall, CM Rice. Interfering with hepatitis C virus RNA replication. Virus Research 2004;102:19-25.
152* Shlomai A, Shaul Y. RNA interference – small RNAs effectively fight viral hepatitis. Liver Int 2004;24:526-31.
153 J Kronke, R Kittler, F Buchholz, és mtsai. Alternative Approaches for Efficient Inhibition of Hepatitis C Virus RNA
Replication by Small Interfering RNAs. J Virol 2004;78:3436-3446.
154Y Takigawa, M Nagano-Fujii, L Deng, és mtsai. Supression of hepatitis C virus replicon by RNA interference
directed against the NS3and NS5B regions of the viral genome. Microbiol Immunol 2004;48:591-598.
155 Liang XS, Lian JQ, Zhou YX, Wan MB. Inhibitor RNA blocks the protein translation mediated by hepatitis C virus
internal ribosome entry site in vivo. World J Gastroenterol 2004; 10: 664-667.
156 WERLE–LAPOSTOLLE, S BOWDEN, S LOCARNINI, és mtsai. Persistence of cccDNA During the Natural
History of Chronic Hepatitis B and Decline During Adefovir Dipivoxil Therapy. Gastroenterology 2004;126: 1750-
1758.
157 G Deng, G Zhou, Y Zhai, és mtsai. Association of Estrogen Receptor a Polymorphisms With Susceptibility to
Chronic Hepatitis B Virus Infection. Hepatology 2004;318-326.
158 Zhang XN, Xiong W, Wang JD, és mtsai. siRNA-mediated inhibition of HBV replication and expression. World J
Gastroenterol 2004;10:2967-2971.
159 Donaldson PT. Genetics of autoimmune and viral liver diseases; understanding the issues. J Hepatol 2004;41:327-
332.
160 C SELMI, MJ MAYO, N BACH, és mtsai. Primary Biliary Cirrhosis in Monozygotic and Dizygotic Twins:
Genetics, Epigenetics, and Environment. Gastroenterology 2004;127: 485-492.
161 L Xu, M Sakalian, Z Shen, és mtsai. Cloning the Human Betaretrovirus Proviral Genome From Patients With
Primary Biliary Cirrhosis. Hepatology 2004;39:151-156.
162 Lakatos PL, Bajnok E, Tornai I, Folhoffer A, Horvath A, Lakatos P, Habior A, Szalay F. Insulin-like growth factor I
(IGF-I) gene microsatellite repeat and collagen type Ia1 Sp1 polymorphism (COLIA1) and bone disease in primary
biliary cirrhosis (PBC). Eur J Gastroenterol Hepatol 2004;16:753-9.
163 C Pauli-Magnus, R Kerb, K Fattinger, és mtsai. BSEP and MDR3 Haplotype Structure in Healthy Caucasians,
Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Hepatology 2004;39:779-791.
164 JM Stapelbroek, CW Bollen, JKP van Amstel, és mtsai. The H1069Q mutation in ATP7B is associated with late and
neurologic presentation in Wilson disease: results of a meta-analysis. J Hepatol 2004;41:758-763.
165 K Wiencke, AS Louka, A Spurkland, és mtsai. Association of matrix metalloproteinase-1 and -3 promoter
polymorphisms with clinical subsets of Norwegian primary sclerosing cholangitis patients. J Hepatol 2004;41:209-214.
166 X Yang, SN Cullen, JH Li, és mtsai. Susceptibility to primary sclerosing cholangitis is associated with
polymorphisms of intercellular adhesion molecule-1. J Hepatol 2004;41:375-379.
167* LWJ Klomp, JC Vargas, SWC van Mil, és mtsai. Characterization of Mutations in ATP8B1 associated With
Hereditary Cholestasis. Hepatology 2004;40:27-38.
168 SWC VAN MIL, W VAN DER WOERD, G VAN DER BRUGGE, és mtsai. Benign Recurrent Intrahepatic
Cholestasis Type 2 Is Caused by Mutations in ABCB11. Gastroenterology 2004;127:379-384.
169 C Namikawa, Z Shu-Ping, JR Vyselaar, és mtsai. Polymorphisms of microsomal triglyceride transfer protein gene
and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol 2004;41: 781-786.
170 E Ip, G Farrell, P Hall, és mtsai. Administration of the Potent PPARa Agonist, Wy-14,643, Reverses Nutritional
Fibrosis and Steatohepatitis in Mice. Hepatology 2004;39:1286-1296.
171 S Fiorucci, E Antonelli, E Distrutti, és mtsai. PAR1 Antagonism Protects Against Experimental Liver Fibrosis. Role
of Proteinase Receptors in Stellate Cell Activation. Hepatology 2004;39:365-375.
172 F Vidal, A Lorenzo, T Auguet, és mtsai Genetic polymorphisms of ADH2, ADH3, CYP4502E1 Dra-I and Pst-I, and
ALDH2 in Spanish men: lack of association with alcoholism and alcoholic liver disease. J Hepatol 2004;41:744-750.
173 J Puppi, C Guillonneau, V Pichard, és mtsai. Long term transgene expression by hepatocytes transduced with
retroviral vectors requires induction of immune tolerance to the transgene. J Hepatol 2004;41:222-228.
174 Ralf Thorsten Henke,1 Bassem R. Haddad, SE Kim, és mtsai. Overexpression of the Nuclear Receptor Coactivator
AIB1 (SRC-3) during Progression of Pancreatic Adenocarcinoma. Clin Cancer Res 2004;10:6134-6142.
175 MM Al-Aynati, N Radulovich, RH Riddell, MS Tsao. Epithelial-Cadherin and b-Catenin Expression Changes in
Pancreatic Intraepithelial Neoplasia. Clin Cancer Res 2004;10: 1235-1240.
176 CA Iacobuzio-Donahue, MS van der Heijden, MR Baumgartner, és mtsai. Large-Scale Allelotype of
Pancreaticobiliary Carcinoma Provides Quantitative Estimates of Genome-Wide Allelic Loss. Cancer Res 2004;64:
871-875.
177 N Sato, N Fukushima, A Maitra, és mtsai. Gene Expression Profiling Identifies Genes Associated with Invasive
Intraductal Papillary Mucinous Neoplasms of the Pancreas. Am J Pathol 2004;164:903-914.
178 A Handra-Luca, A Couvelard, C Degott, JF Flejou. Correlation between patterns of DNA mismatch repair hmlh1
and hmsh2 protein expression and progression of dysplasia in intraductal papillary mucinous neoplasms of the pancreas.
Wirchows Arch 2004;444:235-238.
179 LE Jones, MJ Humphreys, F Campbell, és mtsai. Comprehensive Analysis of Matrix Metalloproteinase and Tissue
Inhibitor Expression in Pancreatic Cancer: Increased Expression of Matrix Metalloproteinase-7 Predicts Poor Survival.
Clin Cancer Res 2004;10: 2832-2845.
180 Wang Y, Yamaguchi Y, Watanabe H, és mtsai. Detection of p53 Gene Mutations in the Supernatant of Pancreatic
Juice and Plasma from Patients with Pancreatic Carcinomas. Pancreas 2004;28:13-19.
181* T Yoshida, S Ohnami, K Aoki, és mtsai. Development of gene therapy to target pancreatic Cancer. Cancer Sci 2004;
95: 283–289
182 T Noro, K Miyake, N Suzuki-Miyake, és mtsai. Adeno-Associated Viral Vector-Mediated Expression of Endostatin
Inhibits Tumor Growth and Metastasis in an Orthotropic Pancreatic Cancer Model in Hamsters. 2004;64:7486-7490.
183 HQ XIONG, JL ABBRUZZESE, E LIN,és mtsai. NF-kB ACTIVITY BLOCKADE IMPAIRS THE ANGIOGENIC
POTENTIAL OF HUMAN PANCREATIC CANCER CELLS. Int J Cancer 2004;108:181-188.
184 Tepel J, Kruse MJ, March C, és mtsai. Terminally Modified Oligodeoxynucleotides Directed Against p53 in an
Orthotopic Xenograft Model: A Novel Adjuvant Treatment Strategy for Pancreatic Ductal Carcinoma. Pancreas
2004;28:1-12.
185 Sunamura N, Hamada H, Motoi F, és mtsai. Oncolytic Virotherapy as a Novel Strategy for Pancreatic Cancer.
Pancreas 2004;28:326-329.
186 Nozawa F, Itami A, Saruc M, és mtsai. The Combination of Tumor Necrosis Factor-Related Apoptosis-Inducing
Ligand (TRAIL/Apo2L) and Genistein Is Effective in Inhibiting Pancreatic Cancer Growth. Pancreas 2004;29:45-52.
187 GR Chandak, MM Idris, DN Reddy, és mtsai. Absence of PRSS1 mutations and association of SPINK1 trypsin
inhibitor mutations in hereditary and non-hereditary chronic pancreatitis. Gut 2004;53:723-728.
188 PC Zamecnik, MK Raychowdhury, DR Tabatadze, HF Cantiello. Reversal of cystic fibrosis phenotype in a cultured
d508 cystic fibrosis transmembrane conductance regulator cell line by oligonucleotide insertion. PNAS 2004;101:8150-
8155.
